A soluble guanylate cyclase stimulator, BAY 41-8543, preserves right ventricular function in experimental pulmonary embolism

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2013, Pages 205-211

  Watts, John A ^a   Gellar, Michael A ^a   Fulkerson, Mary Beth K ^a   Kline, Jeffrey A ^a,b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

BAY 41 8543; Pulmonary embolism; Pulmonary heart disease; Pulmonary vascular resistance; Right ventricle; Soluble guanylate cyclase stimulator

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; MICROSPHERE; POLYSTYRENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EX VIVO STUDY; HEART RATE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART STROKE VOLUME; IN VIVO STUDY; JUGULAR VEIN; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; HEMODYNAMICS; MALE; MORPHOLINES; PLEURAL EFFUSION; PULMONARY EMBOLISM; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; TROPONIN I; VENTRICULAR FUNCTION, RIGHT;

EID: 84874560853     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.10.009     Document Type: Article

References (49)

1. Piazza G., Goldhaber S.Z. Acute pulmonary embolism: part I: epidemiology and diagnosis. Circulation 2006, 114(2):e28-e32.
2. Tapson V.F. Acute pulmonary embolism. N Engl J Med 2008, 358(10):1037-1052.
3. Torbicki A., Perrier A., Konstantinides S., Agnelli G., Galie N., Pruszczyk P., et al. Task force for the diagnosis and management of acute pulmonary embolism of the European society of cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task force for the diagnosis and management of acute pulmonary embolism of the European society of cardiology (ESC). Eur Heart J 2008, 29(18):2276-2315.
4. Becattini C., Agnelli G. Predictors of mortality from pulmonary embolism and their influence on clinical management. Thromb Haemost 2008, 100(5):747-751.
5. Kreit J.W. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest 2004, 125(4):1539-1545.
6. Schoepf U.J., Kucher N., Kipfmueller F., Quiroz R., Costello P., Goldhaber S.Z. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004, 110(20):3276-3280.
7. Ten Wolde M., Sohne M., Quak E., Mac Gillavry M.R., Buller H.R. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004, 164(15):1685-1689.
8. Watts J.A., Marchick M.R., Kline J.A. Right ventricular heart failure from pulmonary embolism: key distinctions from chronic pulmonary hypertension. J Card Fail 2010, 16(3):250-259.
9. Goldhaber S.Z., Elliott C.G. Acute pulmonary embolism: part II: risk stratification, treatment, and prevention. Circulation 2003, 108(23):2834-2838.
10. Kline J.A., Hernandez-Nino J., Rose G.A., Norton H.J., Camargo C.A. Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism. Crit Care Med 2006, 34(11):2773-2780.
11. Stevinson B.G., Hernandez-Nino J., Rose G., Kline J.A. Echocardiographic and functional cardiopulmonary problems six months after first-time pulmonary embolism in previously healthy patients. Eur Heart J 2007, 28:2517-2524.
12. Watts J.A., Zagorski J., Gellar M.A., Stevinson B.G., Kline J.A. Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J Mol Cell Cardiol 2006, 41(2):296-307.
13. Watts J.A., Gellar M.A., Obraztsova M., Kline J.A., Zagorski J. Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in rats. Int J Exp Pathol 2008, 89(4):389-399.
14. Watts J.A., Gellar M.A., Stuart L., Obraztsova M., Kline J.A. Proinflammatory events in right ventricular damage during pulmonary embolism: effects of treatment with ketorolac in rats. J Cardiovasc Pharmacol 2009, 54(246):252.
15. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. American college of chest physicians. Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008, 133(6 Suppl):454S-545S.
16. Murad F. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006, 355:2003-2011.
17. Stasch J.P., Pacher P., Evgenov O.V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011, 123(20):2263-2273.
18. Cau S.B., Dias-Junior C.A., Montenegro M.F., de Nucci G., Antunes E., Tanus-Santos J.E. Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism. Eur J Pharmacol 2008, 581(1-2):132-137.
19. Watts J.A., Gellar M.A., Fulkerson M.B.K., Kline J.A. Pulmonary vascular reserve during experimental pulmonary embolism: effects of a soluble guanylate cyclase stimulator, BAY 41-8543. Crit Care Med 2011, 39(12):2700-2704.
20. Evgenov O.V., Pacher P., Schmidt P.M., Hasko G., Schmidt H.H., Stasch J.P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006, 5(9):755-768.
21. Runyon M.S., Gellar M.A., Sanapareddy N., Kline J.A., Watts J.A. Development and comparison of a minimally-invasive model of autologous clot pulmonary embolism in Sprague-Dawley and Copenhagen rats. Thromb J 2010, 8(3).
22. Meyer T., Binder L., Hruska N., Luthe H., Buchwald A.B. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000, 36(5):1632-1636.
23. Watts J.A., Gellar M.A., Fulkerson M.B.K., Das S., Kline J.A. Arginase depletes plasma L-arginine and decreases pulmonary vascular reserve during experimental pulmonary embolism. Pulm Pharm Therap 2012, 25:48-54.
24. Zagorski J., Gellar M.A., Obraztsova M., Kline J.A., Watts J.A. Inhibition of CINC-1 decreases right ventricular damage caused by experimental pulmonary embolism in rats. J Immunol 2007, 179(11):7820-7826.
25. Zagorski J., Sanapareddy N., Gellar M.A., Kline J.A., Watts J.A. Transcriptional profile of right ventricular tissue during acute pulmonary embolism in rats. Physiol Genomics 2008, 34:101-111.
26. Jones A.E., Watts J.A., Debelak J.P., Thornton L.R., Younger J.G., Kline J.A. Inhibition of prostaglandin synthesis during polystyrene microsphere-induced pulmonary embolism in the rat. Am J Physiol Lung Cell Mol Physiol 2003, 284(6):L1072-L1081.
27. Smulders Y.M. Contribution of pulmonary vasoconstriction to haemodynamic instability after acute pulmonary embolism. Implications for treatment?. Neth J Med 2001, 58(6):241-247.
28. Breuer J., Meschig R., Breuer H.W., Arnold G. Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin. J Cardiovasc Pharmacol 1985, 7(Suppl. 7):64-66.
29. Battistini B. Modulation and roles of the endothelins in the pathophysiology of pulmonary embolism. Can J Physiol Pharmacol 2003, 81(6):555-569.
30. Toba M., Nagaoka T., Morio Y., Sato K., Uchida K., Homma N., et al. Involvement of Rho kinase in the pathogenesis of acute pulmonary embolism-induced polystyrene microspheres in rats. Am J Physiol Lung Cell Mol Physiol 2010, 298(3):L297-L303.
31. Coggins M.P., Bloch K.D. Nitric oxide in the pulmonary vasculature. Arterioscler Thromb Vasc Biol 2007, 27(9):1877-1885.
32. Dias-Junior C.A., Gladwin M.T., Tanus-Santos J.E. Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radic Biol Med 2006, 41(12):1764-1770.
33. Souza-Silva A.R., Dias-Junior C.A., Uzuelli J.A., Moreno H., Evora P.R., Tanus-Santos J.E. Hemodynamic effects of combined sildenafil and L-arginine during acute pulmonary embolism-induced pulmonary hypertension. Eur J Pharmacol 2005, 524(1-3):126-131.
34. Bottiger B.W., Motsch J., Dorsam J., Mieck U., Gries A., Weimann J., et al. Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary microembolism in piglets. Chest 1996, 110(4):1041-1047.
35. Tanus-Santos J.E., Moreno H., Zappellini A., de Nucci G. Small-dose inhaled nitric oxide attenuates hemodynamic changes after pulmonary air embolism in dogs. Anesth Analg 1999, 88(5):1025-1029.
36. Szold O., Khoury W., Biderman P., Klausner J.M., Halpern P., Weinbroum A.A. Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: a report of four patients and review of the literature. Lung 2006, 184(1):1-5.
37. Dias-Junior C.A., Tanus-Santos J.E. Hemodynamic effects of sildenafil interaction with a nitric oxide donor compound in a dog model of acute pulmonary embolism. Life Sci 2006, 79(5):469-474.
38. Watts J.A., Marchick M.R., Gellar M.A., Kline J.A. Up-regulation of arginase II contributes to pulmonary vascular endothelial cell dysfunction during experimental pulmonary embolism. Pulm Pharmacol Therap 2011, 24407-24413.
39. Morris S.M. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 2009, 157(6):922-930.
40. Kline J.A., Marchick M.R., Hogg M.M. Reduction in plasma haptoglobin in humans with acute pulmonary embolism causing tricuspid regurgitation. J Thromb Haemost 2009, 7(9):1597-1599.
41. Zagorski J., Marchick M.R., Kline J.A. Rapid clearance of circulating haptoglobin from plasma during acute pulmonary embolism in rats results in HMOX1 up-regulation in peripheral blood leukocytes. J Thromb Haemost 2010, 8(2):389-396.
42. Rother R.P., Bell L., Hillmen P., Gladwin M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. J Am Med Assoc 2005, 293(13):1653-1662.
43. Evgenov O.V., Kohane D.S., Bloch K.D., Stasch J.P., Volpato G.P., Bellas E., et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Resp Crit Care Med 2007, 176(11):1138-1145.
44. Badejo A.M., Nossaman V.E., Pankey E.A., Bhartiya M., Kannadka C.B., Murthy S.N., et al. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide. Am J Physiol Heart Circ Physiol 2010, 299(4):H1153-H1159.
45. Appavu S.K.M. Is there a role for soluble guanylate cyclase stimulators in acute pulmonary embolism?. Crit Care Med 2011, 39(12):2773-2774.
46. Melot C., Vermeulen F., Maggiorini M., Gilbert E., Naeije R. Site of pulmonary vasodilation by inhaled nitric oxide in microembolic lung injury. Am J Resp Crit Care Med 1997, 156(1):75-85.
47. Lee J.H., Kim S., Park B.K., Kim W.S., Kim D.S., Kim W.D., et al. The effect of a combination of inhaled nitric oxide and an endothelinA-receptor antagonist on hemodynamic dysfunction in experimental acute pulmonary thromboembolism. Lung 2005, 183(2):139-149.
48. Light R.W. Pleural effusion due to pulmonary emboli. Curr Opin Pulm Med 2001, 7(4):198-201.
49. Zagorski J., Debelak J., Gellar M., Watts J.A., Kline J.A. Chemokines accumulate in the lungs of rats with severe pulmonary embolism induced by polystyrene microspheres. J Immunol 2003, 171(10):5529-5536.